v3.25.2
Unaudited Interim Condensed Consolidated Statements of Cash Flows - CHF (SFr)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Unaudited Interim Condensed Consolidated Statements of Cash Flows    
Net profit / (loss) for the period SFr (3,314,028) SFr 9,791,493
Adjustments for:    
Net gain on Neurosterix Transaction (117,747) (13,961,900)
Fair value of services received at zero cost recorded as income (105,560)  
Fair value of services received at zero cost recorded as other operating costs 105,560  
Depreciation 4,236 182,742
Value of share-based services 44,098 433,254
Post-employment benefits 2,003 (28,723)
Share of the net loss of associates 2,079,296 530,749
Finance cost / (income) net 33,399 (100,577)
Increase in other financial assets (498) (1,948)
Increase in trade and other receivables (22,926) (477,288)
Decrease in contract asset   10,387
Increase in prepayments (81,430) (272,821)
(Increase) / decrease in other current assets 7,967 (5,000)
Increase / (decrease) in payables and accruals 347,082 (1,013,382)
Decrease in deferred income   (38,401)
Net cash used in operating activities (1,018,548) (4,951,415)
Cash flows from / (used in) investing activities    
Consideration from Neurosterix Transaction 57,673 5,119,754
Legal fees paid for Neurosterix Transaction   (452,798)
Investment in Stalicla Ltd - preferred shares (285,962)  
Investment in Stalicla Ltd - derivative financial instruments (509,067)  
Net cash from / (used in) investing activities (737,356) 4,666,956
Cash flows from financing activities    
Sale of treasury shares 777,546 235,257
Cost paid on sale of treasury shares (25,897) (1,764)
Movements under liquidity agreement 517 1,940
Costs paid on sale of treasury shares - shelf registration   (24,018)
Costs paid on exercise of pre-funded warrants   (36,457)
Principal element of lease payment (3,607) (69,738)
Interest received 3 9,063
Interest paid (1,377) (7,147)
Net cash from financing activities 747,185 107,136
Decrease in cash and cash equivalents (1,008,719) (177,323)
Cash and cash equivalents at the beginning of the period 3,341,738 3,865,481
Exchange difference on cash and cash equivalents (32,025) 99,622
Cash and cash equivalents at the end of the period SFr 2,300,994 SFr 3,787,780